Archives

An EIC Pathfinder Project Unisens One Assay for the Future of GPCR Drug Discovery Hundreds of different types of G protein–coupled receptors (GPCRs) play diverse roles in the human body and are [...]

Novel transferrin receptor antibodies will be designed to deliver therapeutics across the blood-brain barrier

One-third of all drugs target receptors. ISAR Bioscience invents new technologies to advance their development.

RNAs and other nucleic acids are therapeutics of the future. ISAR Bioscience invents methods to deliver them precisely and effectively to their site of action.

The GO-Immun development project combines two innovative technologies for the treatment of Graves' disease and other autoimmune disorders.

An innovative method for generating antibody germinal centers in cell culture—we aim to use this to test and develop new immunological drugs without animal testing.

We are developing 2D and 3D models of Alzheimer's dementia that are unique worldwide. We are already using these models to test the effectiveness of an antibody we developed in the laboratory.

Developing drugs to treat Alzheimer's disease is extremely difficult. To address this, we are developing 2D and 3D models—unique worldwide—that can be used to test new drug candidates.

Great expectations are pinned on the development of disease models based on stem cells. ISAR Bioscience conducts research on models and mechanisms related to Alzheimer's disease and the immune system.

Together with partners in Munich and around the world, ISAR Bioscience is developing novel therapies for the treatment of acute and chronic lung diseases.